[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623934":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":111,"collaborators":11,"id":113,"slug":114,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":9,"eligibilityCriteria":119,"healthyVolunteers":115,"sex":120,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":11,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},{"fullName":5,"class":6},"EUROS","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NEMOST V2","EXPERIMENTAL",null,[13],"Device: NEMOST V2 growing domino",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DEVICE","NEMOST V2 growing domino","The NEMOST spinal implant is a growth domino intended for the surgical treatment of progressive scoliosis in children.",[9],[21],{"name":22,"affiliation":23,"role":24},"Federico Solla, MD","Centre Hospitalier Universitaire de Nice","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Célia Armanet, PHD","CONTACT","+330756848896","carmanet@euros.fr",[32,52,69,84,100],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Hopital Lenval Nice","RECRUITING","Nice","Provence-Alpes-Côte d'Azur Region","06000","France","FR",{"type":41,"coordinates":42},"Point",[43,44],7.26608,43.70313,{"lat":44,"lon":43},[47,51],{"name":48,"role":28,"phone":49,"phoneExt":11,"email":50},"Federico Solla","0492030491","federico.solla@hpu.lenval.com",{"name":48,"role":24,"phone":11,"phoneExt":11,"email":11},{"facility":53,"status":34,"city":54,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"CHU Pellegrin","Bordeaux",{"type":41,"coordinates":56},[57,58],-0.58046,44.84124,{"lat":58,"lon":57},[61,65,66],{"name":62,"role":28,"phone":63,"phoneExt":11,"email":64},"Louis Boissière","0535544142","louis.boissiere@chu-bordeaux.fr",{"name":62,"role":24,"phone":11,"phoneExt":11,"email":11},{"name":67,"role":68,"phone":11,"phoneExt":11,"email":11},"Yan Lefèvre","SUB_INVESTIGATOR",{"facility":70,"status":71,"city":72,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Hospices Civils de Lyon","NOT_YET_RECRUITING","Lyon",{"type":41,"coordinates":74},[75,76],4.84789,45.74906,{"lat":76,"lon":75},[79,83],{"name":80,"role":28,"phone":81,"phoneExt":11,"email":82},"Vincent Cunin","04 27 85 57 95","vincent.cunin@chu-lyon.fr",{"name":80,"role":24,"phone":11,"phoneExt":11,"email":11},{"facility":85,"status":71,"city":86,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Hopital Armand Trousseau","Paris",{"type":41,"coordinates":88},[89,90],2.3488,48.85341,{"lat":90,"lon":89},[93,97,98],{"name":94,"role":28,"phone":95,"phoneExt":11,"email":96},"Raphael Vialle","0144736125","raphael.vialle@aphp.fr",{"name":94,"role":24,"phone":11,"phoneExt":11,"email":11},{"name":99,"role":68,"phone":11,"phoneExt":11,"email":11},"Mathilde Gaumé",{"facility":101,"status":71,"city":86,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":102,"geoPoint":104,"contacts":105},"Hopital Necker",{"type":41,"coordinates":103},[89,90],{"lat":90,"lon":89},[106,110],{"name":107,"role":28,"phone":108,"phoneExt":11,"email":109},"Lotfi Miladi","+33171196282","l.miladi@aphp.fr",{"name":107,"role":24,"phone":11,"phoneExt":11,"email":11},{"type":112,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100623934","post-market-clinical-follow-up-study-of-nemost-v2-100623934",false,"NCT07403084","Post-market Clinical Follow-up Study of NEMOST V2","Post-market Clinical Follow-up Study of NEMOST V2 Growing Domino","Inclusion Criteria:\n\n* Idiopathic, congenital, neuromuscular, or syndromic scoliosis : Progressive spinal deformity not managed by orthopedic treatment, and requiring primary surgical intervention.\n* The patient, as well as their parents or legal guardians, are informed of the participation in the study.\n* Patients aged from 5 to 17 yeas old, excepted the one who still have a potential for growth\n\nExclusion Criteria:\n\n* signs of local inflammation;\n* acute or chronic, local or systemic infections ;\n* non-reducible scoliosis ;\n* pathological obesity ;\n* allergy or intolerance to implanted materials;\n* insufficiency or absence of tissue coverage. The NEMOST implant should not be used in a spine that has already been instrumented or fused.","ALL","5 Years","17 Years",{"count":124,"type":125},140,"ESTIMATED","INTERVENTIONAL",[128],"NA","The NEMOST spinal implant is a growth domino intended for the surgical treatment of progressive scoliosis in children.\n\nAs part of post-market surveillance, EUROS is conducting a retrospective and prospective study to collect clinical and radiological data on the NEMOST growth domino.\n\nRetrospective and prospective multicenter post-market surveillance clinical study.\n\nThis study is interventional, non-randomized, and uncontrolled. The primary objective of this clinical study is to monitor complications related to the NEMOST growth domino during a 5-year postoperative follow-up in patients treated for progressive scoliosis in children.\n\nThe secondary objective of this clinical study is to monitor the performance of the NEMOST growth domino during a 5-year postoperative follow-up in patients treated for progressive scoliosis in children.\n\nThe study will include 140 patients.",[131,132,133],"Scoliosis Neuromuscular","Scoliosis Idiopathic","Consent Forms","2026-02-04",{"date":136,"type":137},"2026-02-11","ACTUAL",{"date":139,"type":137},"2025-12-19",{"date":141,"type":125},"2033-12-19",{"name":5,"class":6},5]